Floatz logo

RED BLOOD CELLS

Relapsing-remitting Multiple Sclerosis (RRMS)

Cellerys AGCell therapyPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

79 Active assets in the Relapsing-remitting Multiple Sclerosis (RRMS) cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

RED BLOOD CELLS is also rated in:

beta-thalassemia majorDormant
B
Indicative ·
62 / 100
View asset →
bronchopulmonary dysplasiaDormant
D
Indicative ·
30 / 100
View asset →
hereditary persistence of fetal hemoglobinDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →